EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

The Use of a Handheld Non-Invasive Vagal Nerve Stimulation (nVNS) Device for the Treatment of Long COVID: A Pilot Randomized Controlled Trial

Ravindra Ganesh iD, Siddhant Yadav, Darrell R Schroeder, Ivana T Croghan iD, Jennifer Hanson, Megan Erickson, Shawn Fokken, Sara Seegmiller, Stephanie L Grach iD, Elizabeth A Gilman iD, Ryan T Hurt, Michael R Mueller iD

Journal of Primary Care & Community Health · 2026-07 · 17

DOI: 10.1177/21501319261473073 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Primary Care & Community Health, online erschienen am 25.07.2026. Verfasst von Ravindra Ganesh und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Division of General Internal Medicine, Mayo Clinic, Rochester, MN, USA. Hauptthemen laut MEDLINE: Post-Acute COVID-19 Syndrome, Vagus Nerve Stimulation. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCATS NIH HHS, Division of General Internal Medicine, National Center for Advancing Translational Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Long-term symptoms following infection with acute respiratory syndrome coronavirus-2 (SARS-CoV-2), termed post-acute sequelae of SARS-CoV-2 infection (PASC) or Long COVID (LC), persist beyond 90 days and may impact at least 10% of patients with acute infection. The exact cause of LC remains unknown, but several theories include persistent viral particles, immune dysfunction, and autonomic nervous system (ANS) imbalance, particularly involving the vagus nerve. Given the role of the vagus nerve in inflammation regulation, vagal nerve stimulation (VNS) is being explored as a treatment option. The present study aimed to evaluate the feasibility, safety, and exploratory effects of a handheld external transcutaneous cervical non-invasive VNS (tcVNS) on the primary endpoint of Post-COVID Functional Status (PCFS) grade, alongside secondary outcomes such as LC-related fatigue and other symptoms.

Methods

Participants from our Post COVID Care Clinic were randomized into treatment (tcVNS treatments two minutes, three times a day) and control (no VNS) groups for a study period of 12 weeks. Participants completed validated questionnaires, PET-CT scans, and inflammatory cytokines at baseline and 12 weeks.

Results

All randomized patients (8 tcVNS, 10 control) completed the 12-week study. Participants randomized to tcVNS were observed to have improvements in PHQ-9, PROMIS-F, and COMPASS-31 when compared to controls, but these differences were not statistically significant. Cortisol and DHEA were also observed to increase less in the tcVNS group when compared to the control group, but these changes were also not statistically significant. Conclusions tcVNS was well tolerated and may be a promising therapeutic approach for LC, a chronic disease with no approved treatments and very low rates of complete recovery.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Post-Acute COVID-19 SyndromeVagus Nerve StimulationAdultAgedFemaleHumansMaleMiddle AgedPilot ProjectsTreatment Outcome

Stichwörter der Autor:innen

COVIDdisease managementhealth outcomesimpact evaluationprogam evaluation

Autor:innen und Institutionen

  • Department of Internal Medicine, Division of General Internal Medicine, Mayo Clinic, Rochester, MN, USA.
  • Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
  • Department of Internal Medicine, Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
  • Department of Internal Medicine, Division of Endocrinology, Diabetes, Metabolism and Nutrition, Mayo Clinic, Rochester, MN, USA.

ORCID-Profile: Ravindra Ganesh, Ivana T Croghan, Stephanie L Grach, Elizabeth A Gilman, Michael R Mueller

Förderung

  • NCATS NIH HHS
  • Division of General Internal Medicine
  • National Center for Advancing Translational Sciences
  • GHR Foundation

Zitieren

APA

Ganesh, R., Yadav, S., Schroeder, D. R., Croghan, I. T., Hanson, J., Erickson, M., Fokken, S., Seegmiller, S., Grach, S. L., Gilman, E. A., Hurt, R. T., & Mueller, M. R. (2026). The Use of a Handheld Non-Invasive Vagal Nerve Stimulation (nVNS) Device for the Treatment of Long COVID: A Pilot Randomized Controlled Trial. Journal of Primary Care & Community Health, 17. https://doi.org/10.1177/21501319261473073

Vancouver

Ganesh R, Yadav S, Schroeder DR, Croghan IT, Hanson J, Erickson M, et al. The Use of a Handheld Non-Invasive Vagal Nerve Stimulation (nVNS) Device for the Treatment of Long COVID: A Pilot Randomized Controlled Trial. Journal of Primary Care & Community Health. 2026;17. doi:10.1177/21501319261473073

BibTeX
@article{Ganesh2026,
  author = {Ganesh, Ravindra and Yadav, Siddhant and Schroeder, Darrell R and Croghan, Ivana T and Hanson, Jennifer and Erickson, Megan and Fokken, Shawn and Seegmiller, Sara and Grach, Stephanie L and Gilman, Elizabeth A and Hurt, Ryan T and Mueller, Michael R},
  title = {The Use of a Handheld Non-Invasive Vagal Nerve Stimulation (nVNS) Device for the Treatment of Long COVID: A Pilot Randomized Controlled Trial},
  journal = {Journal of Primary Care & Community Health},
  year = {2026},
  volume = {17},
  doi = {10.1177/21501319261473073}
}
Kostenlos starten →